• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

英国重型β地中海贫血的生存率：来自英国地中海贫血登记处的数据。

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

作者信息

Modell B, Khan M, Darlison M

出版信息

Lancet. 2000 Jun 10;355(9220):2051-2. doi: 10.1016/S0140-6736(00)02357-6.

DOI:10.1016/S0140-6736(00)02357-6
PMID:10885361
Abstract

About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.

摘要

在英国，约50%的重型β地中海贫血患者在35岁前死亡，主要原因是传统的铁螯合疗法过于繁琐，难以完全坚持。患者需要一个个性化的治疗方案，纳入新的、更易耐受的方法。

相似文献

1
Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.英国重型β地中海贫血的生存率：来自英国地中海贫血登记处的数据。
Lancet. 2000 Jun 10;355(9220):2051-2. doi: 10.1016/S0140-6736(00)02357-6.
2
Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.去铁胺和去铁酮联合螯合疗法治疗重型β地中海贫血：年轻地中海贫血患者的依从性及意见
Hemoglobin. 2014;38(2):111-4. doi: 10.3109/03630269.2013.867407. Epub 2013 Dec 18.
3
Morbidity and mortality of iron intoxication in adult patients with thalassemia major, and effectiveness of chelation.重型地中海贫血成年患者铁中毒的发病率和死亡率以及螯合治疗的有效性。
Transfus Sci. 2000 Dec;23(3):255-6. doi: 10.1016/s0955-3886(00)00100-4.
4
Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.伊朗重型β地中海贫血患者去铁胺注射的依从性
Transfus Med. 2012 Apr;22(2):104-7. doi: 10.1111/j.1365-3148.2011.01130.x. Epub 2011 Dec 30.
5
A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.一种用于评估和改善地中海贫血患者去铁胺铁螯合治疗依从性的简单模型。
Ann N Y Acad Sci. 2005;1054:486-91. doi: 10.1196/annals.1345.065.
6
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.去铁酮治疗改善重型地中海贫血患者生存率：一项在意大利地中海贫血和血红蛋白病协会支持下开展的前瞻性多中心随机临床试验。
Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51. doi: 10.1016/j.bcmd.2009.01.002. Epub 2009 Feb 23.
7
Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.对重型β地中海贫血年轻患者进行连续MRI扫描前瞻性评估心肌和肝脏铁含量的四年研究：不同螯合方案的比较
Eur J Haematol. 2007 Jan;78(1):52-7. doi: 10.1111/j.0902-4441.2006.t01-1-EJH3013.x. Epub 2006 Sep 28.
8
Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.地中海贫血患者的流行病学及螯合疗法对葡萄糖稳态的影响
J Pediatr Endocrinol Metab. 1998;11 Suppl 3:867-9.
9
Compliance with iron chelation therapy in beta thalassaemia.β地中海贫血患者对铁螯合疗法的依从性。
Paediatr Nurs. 1998 Oct;10(8):17-8, 20.
10
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.口服与皮下铁螯合疗法预防重型β地中海贫血患者主要内分泌病的比较
Hemoglobin. 2006;30(2):257-62. doi: 10.1080/03630260600642609.

引用本文的文献

1
New Approaches and Strategies for the Repurposing of Iron Chelating/Antioxidant Drugs for Diseases of Free Radical Pathology in Medicine.铁螯合/抗氧化药物在医学中用于自由基病理疾病的重新利用的新方法和策略。
Antioxidants (Basel). 2025 Aug 10;14(8):982. doi: 10.3390/antiox14080982.
2
Genetic landscape and hematological profiling of thalassemia in patients from the Malwa region, Central India.印度中部马尔瓦地区地中海贫血患者的基因图谱与血液学分析
Mol Genet Genomics. 2025 Apr 12;300(1):42. doi: 10.1007/s00438-025-02245-7.
3
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia.
β地中海贫血间接成本与人文负担的系统文献综述
Ther Adv Hematol. 2024 Sep 18;15:20406207241270872. doi: 10.1177/20406207241270872. eCollection 2024.
4
Survival and causes of death in patients with alpha and beta-thalassemia in Northern Thailand.泰国北部的阿尔法和贝塔地中海贫血患者的生存和死亡原因。
Ann Med. 2024 Dec;56(1):2338246. doi: 10.1080/07853890.2024.2338246. Epub 2024 Apr 11.
5
Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia.西班牙血红蛋白病和罕见贫血登记处（REHem-AR）：β-地中海贫血患者的人口统计学、并发症和治疗情况。
Ann Hematol. 2024 May;103(5):1525-1539. doi: 10.1007/s00277-024-05694-z. Epub 2024 Mar 23.
6
A cross-sectional study: caregiver burden and related determinants of adult patients with β-thalassemia major in mainland China.一项横断面研究：中国大陆重型β地中海贫血成年患者的照顾者负担及相关决定因素
BMC Nurs. 2024 Mar 4;23(1):151. doi: 10.1186/s12912-024-01826-y.
7
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.药物选择和剂量、医学中的最佳治疗和风险/效益评估：铁螯合剂药物的范例。
Int J Mol Sci. 2023 Nov 25;24(23):16749. doi: 10.3390/ijms242316749.
8
Cardiac complications in thalassemia throughout the lifespan: Victories and challenges.地中海贫血症患者一生中的心脏并发症：胜利与挑战。
Ann N Y Acad Sci. 2023 Dec;1530(1):64-73. doi: 10.1111/nyas.15078. Epub 2023 Oct 30.
9
Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.转铁蛋白超负荷的儿科患者应用地拉罗司颗粒和分散片的依从性和临床获益：一项随机、开放标签、多中心、二期研究。
Haematologica. 2024 May 1;109(5):1413-1425. doi: 10.3324/haematol.2023.283133.
10
Economic burden of adult patients with β-thalassaemia major in mainland China.β-重型地中海贫血成年患者的经济负担。
Orphanet J Rare Dis. 2023 Aug 29;18(1):252. doi: 10.1186/s13023-023-02858-4.